CSL Limited (CSL.AX)
| Previous close | 268.30 |
| Open | 267.00 |
| Bid | 263.92 x 13700 |
| Ask | 263.95 x 21700 |
| Day's range | 263.95 - 267.51 |
| 52-week range | 242.00 - 322.75 |
| Volume | 541,781 |
| Avg. volume | 831,412 |
| Market cap | 120.129B |
| Beta (5Y monthly) | 0.12 |
| PE ratio (TTM) | 34.91 |
| EPS (TTM) | 7.56 |
| Earnings date | 18 Feb 2021 |
| Forward dividend & yield | 2.70 (1.01%) |
| Ex-dividend date | 04 Mar 2021 |
| 1y target est | 151.95 |
- PR Newswire
Seqirus Publishes New Real-World Evidence Supporting the Effectiveness of Adjuvanted Seasonal Influenza Vaccine in Adults 65 Years and Older in Clinical Infectious Diseases
Seqirus, a global leader in influenza prevention, today announced the publication of new real-world evidence (RWE) on the company's MF59® adjuvanted, trivalent influenza vaccine (aTIV) in the peer-reviewed medical journal Clinical Infectious Diseases.1 Study results indicate aTIV was more effective in reducing influenza-related medical encounters compared with standard egg-based quadrivalent influenza vaccine (QIVe) and high-dose trivalent influenza vaccine (TIV-HD) among adults 65 years and older during the 2017/18 and 2018/19 U.S. influenza seasons.1
- PR Newswire
Terumo Blood and Cell Technologies and CSL Plasma Announce Collaboration to Deliver New Plasma Collection Platform
Terumo Blood and Cell Technologies and CSL Plasma today announce a collaboration to deliver a new plasma collection platform at CSL Plasma U.S. collection centers. A clinical trial of the investigational plasmapheresis device began earlier this month, and introduction of the new platform is subject to U.S. Food and Drug Administration device clearance, at which time the parties will provide further comment.
- Simply Wall St.
Here's Why We Think CSL (ASX:CSL) Is Well Worth Watching
Like a puppy chasing its tail, some new investors often chase 'the next big thing', even if that means buying 'story...
